| Patent application number | Description | Published |
|---|
| 20080286877 | Displacement assay for detection of small molecules - Complex of an anti-cocaine aptamer and the dye diethylthiotricarbocyanine behaves as a calorimetric sensor with attenuation in absorbance at 760 nm for cocaine in the concentration range of 2-5000 μM. Mechanistic studies indicate an intermolecular displacement of the dye as the mechanism of action of the sensor. As the dye is insoluble in buffer, cocaine binding can be detected as displaced dye precipitates and supernatant decolorizes. | 11-20-2008 |
| 20090004663 | Real-Time Assays Of Neuro-Humoral Factors To Assess Cardiovascular Stress - The present invention relates to rapid assays for neuro-humoral factors modulated in response to cardiovascular stress and integration of data obtained from such assays to provide profiles of response to cardiovascular stress that can guide therapy. | 01-01-2009 |
| 20090270508 | GluR2 receptor modulators - The present invention provides for compositions and methods for modulating the GluR2 receptor. It is based, at least in part, on the discovery, by X-ray crystallography, that a known GluR2 agonist binds to the receptor in two different orientations, thereby diminishing its potency. The present invention provides for structural alternatives in which alternative binding possibilities are substantially eliminated. | 10-29-2009 |
| 20090292119 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS - The present invention provides improved methods for synthesizing novel benzothiazepine compounds. In particular, the invention relates to a new method that generally is used to make the substituted 2,3,4,5-tetrahydro-1,4-benzothiazepine compounds of a general formula | 11-26-2009 |
| 20100114002 | METHOD AND APPARATUS FOR AN EXTRACORPOREAL CONTROL OF BLOOD GLUCOSE - A method for controlling the blood glucose level of a patient and periodically calibrating the glucose sensor using a calibration solution. The method controls the level of blood glucose in a patient through an extracorporeal blood circuit by: withdrawing blood from a vascular system in the patient to the extracorporeal circuit; removing ultrafiltrate from the withdrawn blood in the circuit; determining a level of glucose present in the blood based on the removed ultrafiltrate; infusing at least a portion of the removed ultrafiltrate and the withdrawn blood into the vascular system, and infusing insulin into the patient based on the determined level of glucose. | 05-06-2010 |
| 20100151465 | Selective Capture and Release of Analytes - The described subject matter includes techniques and components for minimally invasive, selective capture and release of analytes. An aptamer is selected for its binding affinity with a particular analyte(s). The aptamer is functionalized on a solid phase, for example, microbeads, polymer monolith, microfabricated solid phase, etc. The analyte is allowed to bind to the aptamer, for example, in a microchamber. Once the analyte has been bound, a temperature control sets the temperature to an appropriate temperature at which the captured analyte is released. | 06-17-2010 |
| 20100152440 | NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2) - The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods. | 06-17-2010 |
| 20110065104 | REAL-TIME ASSAYS OF NEURO-HUMORAL FACTORS TO ASSESS CARDIOVASCULAR STRESS - The present invention relates to rapid assays for neuro-humoral factors modulated in response to cardiovascular stress and integration of data obtained from such assays to provide profiles of response to cardiovascular stress that can guide therapy. | 03-17-2011 |
| 20110071124 | Compounds that Inhibit Production of sAPPB and AB and Uses Thereof - The present invention relates to compounds with activity as inhibitors of sAPPβ and Aβ production, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease and pharmaceutical compositions containing such candidate compounds. | 03-24-2011 |
| 20110142816 | THERMOSTABILIZATION OF PROTEINS - Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal under-going a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition. | 06-16-2011 |
